APO Research
Talk to an analyst

APO RESEARCH · REPORT

Nonalcoholic Steatohepatitis Treatment

Compare research editions
View pricing & licenses

Selected research

Market Analysis & Forecast

Global Nonalcoholic Steatohepatitis Treatment Market Analysis and Forecast 2026-2032

31 December 2025197 pages

Choose your research edition.

Industry ResearchNonalcoholic Steatohepatitis Treatment Industry Research Report 2026124 pages · $2,950 USDIndustry Growth & TrendsGlobal Nonalcoholic Steatohepatitis Treatment Industry Growth and Trends Forecast to 2032102 pages · $3,450 USDMarket StructureGlobal Nonalcoholic Steatohepatitis Treatment Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032198 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Nonalcoholic Steatohepatitis Treatment Market Outlook and Growth Opportunities 2026197 pages · $4,250 USDMarket Analysis & ForecastGlobal Nonalcoholic Steatohepatitis Treatment Market Analysis and Forecast 2026-2032197 pages · $4,950 USD

Market perspective

The global Nonalcoholic Steatohepatitis Treatment market is projected to grow from US$ million in 2026 to US$ million by 2032, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.

The North America market for Nonalcoholic Steatohepatitis Treatment is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Europe market for Nonalcoholic Steatohepatitis Treatment is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Read the full market overview

Asia-Pacific market for Nonalcoholic Steatohepatitis Treatment is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The China market for Nonalcoholic Steatohepatitis Treatment is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The major global companies of Nonalcoholic Steatohepatitis Treatment include Arena Pharmaceuticals, Arisaph Pharmaceuticals, Cempra Pharmaceuticals, Galectin Therapeutics, Galmed Pharmaceuticals, Genfit, Gilead, Novo Nordisk and Vivus, etc. In 2025, the world's top three vendors accounted for approximately % of the revenue.

Report Includes

This report presents an overview of global market for Nonalcoholic Steatohepatitis Treatment, market size. Analyses of the global market trends, with historic market revenue data for 2021 - 2025, estimates for 2026, and projections of CAGR through 2032.

This report researches the key producers of Nonalcoholic Steatohepatitis Treatment, also provides the revenue of main regions and countries. Of the upcoming market potential for Nonalcoholic Steatohepatitis Treatment, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Nonalcoholic Steatohepatitis Treatment revenue, market share and industry ranking of main manufacturers, data from 2021 to 2026. Identification of the major stakeholders in the global Nonalcoholic Steatohepatitis Treatment market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, revenue, and growth rate, from 2021 to 2032. Evaluation and forecast the market size for Nonalcoholic Steatohepatitis Treatment revenue, projected growth trends, production technology, application and end-user industry.

Nonalcoholic Steatohepatitis Treatment Segment by Company

Arena Pharmaceuticals

Arisaph Pharmaceuticals

Cempra Pharmaceuticals

Galectin Therapeutics

Galmed Pharmaceuticals

Genfit

Gilead

Novo Nordisk

Vivus

AstraZeneca

GSK

Roche

Nonalcoholic Steatohepatitis Treatment Segment by Type

Solid

Liquid

Nonalcoholic Steatohepatitis Treatment Segment by Application

Drug Store

Hospital

Hospital Pharmacy

Mail Order Pharmacy

Diagnostic Center

Specialized Clinic

Nonalcoholic Steatohepatitis Treatment Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Colombia

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.

2. To present the key players, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Nonalcoholic Steatohepatitis Treatment market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Nonalcoholic Steatohepatitis Treatment and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in market size), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Nonalcoholic Steatohepatitis Treatment.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Revenue of Nonalcoholic Steatohepatitis Treatment in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.

Chapter 4: Detailed analysis of Nonalcoholic Steatohepatitis Treatment company competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.

Chapter 5: Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 6: Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 7: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Nonalcoholic Steatohepatitis Treatment revenue, gross margin, and recent development, etc.

Chapter 8: North America by type, by application and by country, revenue for each segment.

Chapter 9: Europe by type, by application and by country, revenue for each segment.

Chapter 10: China type, by application, revenue for each segment.

Chapter 11: Asia (excluding China) type, by application and by region, revenue for each segment.

Chapter 12: South America, Middle East and Africa by type, by application and by country, revenue for each segment.

Chapter 13: The main concluding insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Global Nonalcoholic Steatohepatitis Treatment Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Table 2. Solid Major Player Table 3. Liquid Major Player Table 4. Global Nonalcoholic Steatohepatitis Treatment Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Table 5. Drug Store Major Player Table 6. Hospital Major Player Table 7. Hospital Pharmacy Major Player Table 8. Mail Order Pharmacy Major Player Table 9. Diagnostic Center Major Player Table 10. Specialized Clinic Major Player Table 11. Nonalcoholic Steatohepatitis Treatment Industry Trends Table 12. Nonalcoholic Steatohepatitis Treatment Industry Drivers Table 13. Nonalcoholic Steatohepatitis Treatment Industry Opportunities and Challenges Table 14. Nonalcoholic Steatohepatitis Treatment Industry Restraints Table 15. Global Nonalcoholic Steatohepatitis Treatment Market Size Growth Rate (CAGR) by Region (US$ Million): 2021 VS 2025 VS 2032 Table 16. Global Nonalcoholic Steatohepatitis Treatment Market Size by Region (2021-2026) & (US$ Million) Table 17. Global Nonalcoholic Steatohepatitis Treatment Market Share by Region (2021-2026) Table 18. Global Nonalcoholic Steatohepatitis Treatment Market Size by Region (2027-2032) & (US$ Million) Table 19. Global Nonalcoholic Steatohepatitis Treatment Market Share by Region (2027-2032) Table 20. Global Nonalcoholic Steatohepatitis Treatment Revenue by Players (US$ Million) & (2021-2026) Table 21. Global Nonalcoholic Steatohepatitis Treatment Revenue Market Share by Players (2021-2026) Table 22. Global Nonalcoholic Steatohepatitis Treatment Key Players Ranking, 2024 VS 2025 VS 2026 Table 23. Global Nonalcoholic Steatohepatitis Treatment Key Players Headquarters & Area Served Table 24. Global Nonalcoholic Steatohepatitis Treatment Players, Product Type & Application Table 25. Global Nonalcoholic Steatohepatitis Treatment Players Establishment Date Table 26. Global Players Market Concentration Ratio (CR5 and HHI) Table 27. Global Nonalcoholic Steatohepatitis Treatment by Players Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 28. Global Nonalcoholic Steatohepatitis Treatment Revenue by Type 2021 VS 2025 VS 2032 (US$ Million) Table 29. Global Nonalcoholic Steatohepatitis Treatment Revenue by Type (2021-2026) & (US$ Million) Table 30. Global Nonalcoholic Steatohepatitis Treatment Revenue by Type (2027-2032) & (US$ Million) Table 31. Global Nonalcoholic Steatohepatitis Treatment Revenue Market Share by Type (2021-2026) Table 32. Global Nonalcoholic Steatohepatitis Treatment Revenue Market Share by Type (2027-2032) Table 33. Global Nonalcoholic Steatohepatitis Treatment Revenue by Application 2021 VS 2025 VS 2032 (US$ Million) Table 34. Global Nonalcoholic Steatohepatitis Treatment Revenue by Application (2021-2026) & (US$ Million) Table 35. Global Nonalcoholic Steatohepatitis Treatment Revenue by Application (2027-2032) & (US$ Million) Table 36. Global Nonalcoholic Steatohepatitis Treatment Revenue Market Share by Application (2021-2026) Table 37. Global Nonalcoholic Steatohepatitis Treatment Revenue Market Share by Application (2027-2032) Table 38. Arena Pharmaceuticals Company Information Table 39. Arena Pharmaceuticals Business Overview Table 40. Arena Pharmaceuticals Nonalcoholic Steatohepatitis Treatment Revenue and Gross Margin (US$ Million) & (2021-2026) Table 41. Arena Pharmaceuticals Nonalcoholic Steatohepatitis Treatment Product Portfolio Table 42. Arena Pharmaceuticals Recent Development Table 43. Arisaph Pharmaceuticals Company Information Table 44. Arisaph Pharmaceuticals Business Overview Table 45. Arisaph Pharmaceuticals Nonalcoholic Steatohepatitis Treatment Revenue and Gross Margin (US$ Million) & (2021-2026) Table 46. Arisaph Pharmaceuticals Nonalcoholic Steatohepatitis Treatment Product Portfolio Table 47. Arisaph Pharmaceuticals Recent Development Table 48. Cempra Pharmaceuticals Company Information Table 49. Cempra Pharmaceuticals Business Overview Table 50. Cempra Pharmaceuticals Nonalcoholic Steatohepatitis Treatment Revenue and Gross Margin (US$ Million) & (2021-2026) Table 51. Cempra Pharmaceuticals Nonalcoholic Steatohepatitis Treatment Product Portfolio Table 52. Cempra Pharmaceuticals Recent Development Table 53. Galectin Therapeutics Company Information Table 54. Galectin Therapeutics Business Overview Table 55. Galectin Therapeutics Nonalcoholic Steatohepatitis Treatment Revenue and Gross Margin (US$ Million) & (2021-2026) Table 56. Galectin Therapeutics Nonalcoholic Steatohepatitis Treatment Product Portfolio Table 57. Galectin Therapeutics Recent Development Table 58. Galmed Pharmaceuticals Company Information Table 59. Galmed Pharmaceuticals Business Overview Table 60. Galmed Pharmaceuticals Nonalcoholic Steatohepatitis Treatment Revenue and Gross Margin (US$ Million) & (2021-2026) Table 61. Galmed Pharmaceuticals Nonalcoholic Steatohepatitis Treatment Product Portfolio Table 62. Galmed Pharmaceuticals Recent Development Table 63. Genfit Company Information Table 64. Genfit Business Overview Table 65. Genfit Nonalcoholic Steatohepatitis Treatment Revenue and Gross Margin (US$ Million) & (2021-2026) Table 66. Genfit Nonalcoholic Steatohepatitis Treatment Product Portfolio Table 67. Genfit Recent Development Table 68. Gilead Company Information Table 69. Gilead Business Overview Table 70. Gilead Nonalcoholic Steatohepatitis Treatment Revenue and Gross Margin (US$ Million) & (2021-2026) Table 71. Gilead Nonalcoholic Steatohepatitis Treatment Product Portfolio Table 72. Gilead Recent Development Table 73. Novo Nordisk Company Information Table 74. Novo Nordisk Business Overview Table 75. Novo Nordisk Nonalcoholic Steatohepatitis Treatment Revenue and Gross Margin (US$ Million) & (2021-2026) Table 76. Novo Nordisk Nonalcoholic Steatohepatitis Treatment Product Portfolio Table 77. Novo Nordisk Recent Development Table 78. Vivus Company Information Table 79. Vivus Business Overview Table 80. Vivus Nonalcoholic Steatohepatitis Treatment Revenue and Gross Margin (US$ Million) & (2021-2026) Table 81. Vivus Nonalcoholic Steatohepatitis Treatment Product Portfolio Table 82. Vivus Recent Development Table 83. AstraZeneca Company Information Table 84. AstraZeneca Business Overview Table 85. AstraZeneca Nonalcoholic Steatohepatitis Treatment Revenue and Gross Margin (US$ Million) & (2021-2026) Table 86. AstraZeneca Nonalcoholic Steatohepatitis Treatment Product Portfolio Table 87. AstraZeneca Recent Development Table 88. GSK Company Information Table 89. GSK Business Overview Table 90. GSK Nonalcoholic Steatohepatitis Treatment Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 91. GSK Nonalcoholic Steatohepatitis Treatment Product Portfolio Table 92. GSK Recent Development Table 93. Roche Company Information Table 94. Roche Business Overview Table 95. Roche Nonalcoholic Steatohepatitis Treatment Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 96. Roche Nonalcoholic Steatohepatitis Treatment Product Portfolio Table 97. Roche Recent Development Table 98. North America Nonalcoholic Steatohepatitis Treatment Revenue by Type (2021-2026) & (US$ Million) Table 99. North America Nonalcoholic Steatohepatitis Treatment Revenue by Type (2027-2032) & (US$ Million) Table 100. North America Nonalcoholic Steatohepatitis Treatment Revenue by Application (2021-2026) & (US$ Million) Table 101. North America Nonalcoholic Steatohepatitis Treatment Revenue by Application (2027-2032) & (US$ Million) Table 102. North America Nonalcoholic Steatohepatitis Treatment Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 103. North America Nonalcoholic Steatohepatitis Treatment Revenue by Country (2021-2026) & (US$ Million) Table 104. North America Nonalcoholic Steatohepatitis Treatment Revenue by Country (US$ Million) & (2027-2032) Table 105. Europe Nonalcoholic Steatohepatitis Treatment Revenue by Type (2021-2026) & (US$ Million) Table 106. Europe Nonalcoholic Steatohepatitis Treatment Revenue by Type (2027-2032) & (US$ Million) Table 107. Europe Nonalcoholic Steatohepatitis Treatment Revenue by Application (2021-2026) & (US$ Million) Table 108. Europe Nonalcoholic Steatohepatitis Treatment Revenue by Application (2027-2032) & (US$ Million) Table 109. Europe Nonalcoholic Steatohepatitis Treatment Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 110. Europe Nonalcoholic Steatohepatitis Treatment Revenue by Country (2021-2026) & (US$ Million) Table 111. Europe Nonalcoholic Steatohepatitis Treatment Revenue by Country (US$ Million) & (2027-2032) Table 112. China Nonalcoholic Steatohepatitis Treatment Revenue by Type (2021-2026) & (US$ Million) Table 113. China Nonalcoholic Steatohepatitis Treatment Revenue by Type (2027-2032) & (US$ Million) Table 114. China Nonalcoholic Steatohepatitis Treatment Revenue by Application (2021-2026) & (US$ Million) Table 115. China Nonalcoholic Steatohepatitis Treatment Revenue by Application (2027-2032) & (US$ Million) Table 116. Asia Nonalcoholic Steatohepatitis Treatment Revenue by Type (2021-2026) & (US$ Million) Table 117. Asia Nonalcoholic Steatohepatitis Treatment Revenue by Type (2027-2032) & (US$ Million) Table 118. Asia Nonalcoholic Steatohepatitis Treatment Revenue by Application (2021-2026) & (US$ Million) Table 119. Asia Nonalcoholic Steatohepatitis Treatment Revenue by Application (2027-2032) & (US$ Million) Table 120. Asia Nonalcoholic Steatohepatitis Treatment Revenue by Region (2021 VS 2025 VS 2032) & (US$ Million) Table 121. Asia Nonalcoholic Steatohepatitis Treatment Revenue by Region (US$ Million) & (2021-2026) Table 122. Asia Nonalcoholic Steatohepatitis Treatment Revenue by Region (US$ Million) & (2027-2032) Table 123. SAMEA Nonalcoholic Steatohepatitis Treatment Revenue by Type (2021-2026) & (US$ Million) Table 124. SAMEA Nonalcoholic Steatohepatitis Treatment Revenue by Type (2027-2032) & (US$ Million) Table 125. SAMEA Nonalcoholic Steatohepatitis Treatment Revenue by Application (2021-2026) & (US$ Million) Table 126. SAMEA Nonalcoholic Steatohepatitis Treatment Revenue by Application (2027-2032) & (US$ Million) Table 127. SAMEA Nonalcoholic Steatohepatitis Treatment Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 128. SAMEA Nonalcoholic Steatohepatitis Treatment Revenue by Country (2021-2026) & (US$ Million) Table 129. SAMEA Nonalcoholic Steatohepatitis Treatment Revenue by Country (US$ Million) & (2027-2032) Table 130. Research Programs/Design for This Report Table 131. Authors List of This Report Table 132. Secondary Sources Table 133. Primary Sources List of Figures Figure 1. Nonalcoholic Steatohepatitis Treatment Image Figure 2. Global Nonalcoholic Steatohepatitis Treatment Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Nonalcoholic Steatohepatitis Treatment Market Size Share 2021 VS 2025 VS 2032 Figure 4. Solid Image Figure 5. Liquid Image Figure 6. Global Nonalcoholic Steatohepatitis Treatment Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Figure 7. Global Nonalcoholic Steatohepatitis Treatment Market Size Share 2021 VS 2025 VS 2032 Figure 8. Drug Store Image Figure 9. Hospital Image Figure 10. Hospital Pharmacy Image Figure 11. Mail Order Pharmacy Image Figure 12. Diagnostic Center Image Figure 13. Specialized Clinic Image Figure 14. Global Nonalcoholic Steatohepatitis Treatment Market Size (US$ Million) & (2021-2032) Figure 15. Global Nonalcoholic Steatohepatitis Treatment Market Size, (US$ Million), 2021 VS 2025 VS 2032 Figure 16. Global Nonalcoholic Steatohepatitis Treatment Market Share by Region: 2021 VS 2025 VS 2032 Figure 17. Global Nonalcoholic Steatohepatitis Treatment Players Revenue Share Top 10 and Top 5 in 2025 Figure 18. Players Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 19. Global Nonalcoholic Steatohepatitis Treatment Revenue by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 20. Global Nonalcoholic Steatohepatitis Treatment Revenue Market Share 2021 VS 2025 VS 2032 Figure 21. Global Nonalcoholic Steatohepatitis Treatment Revenue Market Share by Type (2021-2032) Figure 22. Global Nonalcoholic Steatohepatitis Treatment Revenue by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 23. Global Nonalcoholic Steatohepatitis Treatment Revenue Market Share by Application (2021 VS 2025 VS 2032) Figure 24. Global Nonalcoholic Steatohepatitis Treatment Revenue Market Share by Application (2021-2032) Figure 25. North America Nonalcoholic Steatohepatitis Treatment Revenue YoY Growth (2021-2032) & (US$ Million) Figure 26. North America Nonalcoholic Steatohepatitis Treatment Revenue Share by Type (2021-2032) Figure 27. North America Nonalcoholic Steatohepatitis Treatment Revenue Share by Application (2021-2032) Figure 28. North America Nonalcoholic Steatohepatitis Treatment Revenue Share by Country (2021-2032) Figure 29. United States Nonalcoholic Steatohepatitis Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 30. Canada Nonalcoholic Steatohepatitis Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 31. Mexico Nonalcoholic Steatohepatitis Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 32. Europe Nonalcoholic Steatohepatitis Treatment Revenue YoY Growth (2021-2032) & (US$ Million) Figure 33. Europe Nonalcoholic Steatohepatitis Treatment Revenue Share by Type (2021-2032) Figure 34. Europe Nonalcoholic Steatohepatitis Treatment Revenue Share by Application (2021-2032) Figure 35. Europe Nonalcoholic Steatohepatitis Treatment Revenue Share by Country (2021-2032) Figure 36. Germany Nonalcoholic Steatohepatitis Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 37. France Nonalcoholic Steatohepatitis Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 38. U.K. Nonalcoholic Steatohepatitis Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 39. Italy Nonalcoholic Steatohepatitis Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 40. Spain Nonalcoholic Steatohepatitis Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 41. Russia Nonalcoholic Steatohepatitis Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 42. Netherlands Nonalcoholic Steatohepatitis Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 43. Nordic Countries Nonalcoholic Steatohepatitis Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 44. China Nonalcoholic Steatohepatitis Treatment Revenue YoY Growth (2021-2032) & (US$ Million) Figure 45. China Nonalcoholic Steatohepatitis Treatment Revenue Share by Type (2021-2032) Figure 46. China Nonalcoholic Steatohepatitis Treatment Revenue Share by Application (2021-2032) Figure 47. Asia Nonalcoholic Steatohepatitis Treatment Revenue YoY Growth (2021-2032) & (US$ Million) Figure 48. Asia Nonalcoholic Steatohepatitis Treatment Revenue Share by Type (2021-2032) Figure 49. Asia Nonalcoholic Steatohepatitis Treatment Revenue Share by Application (2021-2032) Figure 50. Asia Nonalcoholic Steatohepatitis Treatment Revenue Share by Region (2021-2032) Figure 51. Japan Nonalcoholic Steatohepatitis Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 52. South Korea Nonalcoholic Steatohepatitis Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 53. India Nonalcoholic Steatohepatitis Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 54. Australia Nonalcoholic Steatohepatitis Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 55. Taiwan Nonalcoholic Steatohepatitis Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 56. Southeast Asia Nonalcoholic Steatohepatitis Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 57. SAMEA Nonalcoholic Steatohepatitis Treatment Revenue YoY Growth (2021-2032) & (US$ Million) Figure 58. SAMEA Nonalcoholic Steatohepatitis Treatment Revenue Share by Type (2021-2032) Figure 59. SAMEA Nonalcoholic Steatohepatitis Treatment Revenue Share by Application (2021-2032) Figure 60. SAMEA Nonalcoholic Steatohepatitis Treatment Revenue Share by Country (2021-2032) Figure 61. Brazil Nonalcoholic Steatohepatitis Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 62. Argentina Nonalcoholic Steatohepatitis Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 63. Chile Nonalcoholic Steatohepatitis Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 64. Colombia Nonalcoholic Steatohepatitis Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 65. Peru Nonalcoholic Steatohepatitis Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 66. Saudi Arabia Nonalcoholic Steatohepatitis Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 67. Israel Nonalcoholic Steatohepatitis Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 68. UAE Nonalcoholic Steatohepatitis Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 69. Turkey Nonalcoholic Steatohepatitis Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 70. Iran Nonalcoholic Steatohepatitis Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 71. Egypt Nonalcoholic Steatohepatitis Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 72. Years Considered Figure 73. Research Process Figure 74. Key Executives Interviewed

Scope & coverage.

Types
  • Solid
  • Liquid
Applications
  • Drug Store
  • Hospital
  • Hospital Pharmacy
  • Mail Order Pharmacy
  • Diagnostic Center
  • Specialized Clinic
Companies covered
  • Arena Pharmaceuticals
  • Arisaph Pharmaceuticals
  • Cempra Pharmaceuticals
  • Galectin Therapeutics
  • Galmed Pharmaceuticals
  • Genfit
  • Gilead
  • Novo Nordisk
  • Vivus
  • AstraZeneca
  • GSK
  • Roche

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Nonalcoholic Steatohepatitis Treatment Market by Type
  3. 1.2.1 Global Nonalcoholic Steatohepatitis Treatment Market Size by Type, 2021 VS 2025 VS 2032
  4. 1.2.2 Solid
  5. 1.2.3 Liquid
  6. 1.3 Nonalcoholic Steatohepatitis Treatment Market by Application
  7. 1.3.1 Global Nonalcoholic Steatohepatitis Treatment Market Size by Application, 2021 VS 2025 VS 2032
  8. 1.3.2 Drug Store
  9. 1.3.3 Hospital
  10. 1.3.4 Hospital Pharmacy
  11. 1.3.5 Mail Order Pharmacy
  12. 1.3.6 Diagnostic Center
  13. 1.3.7 Specialized Clinic
  14. 1.4 Assumptions and Limitations
  15. 1.5 Study Goals and Objectives
2 Nonalcoholic Steatohepatitis Treatment Market Dynamics
  1. 2.1 Nonalcoholic Steatohepatitis Treatment Industry Trends
  2. 2.2 Nonalcoholic Steatohepatitis Treatment Industry Drivers
  3. 2.3 Nonalcoholic Steatohepatitis Treatment Industry Opportunities and Challenges
  4. 2.4 Nonalcoholic Steatohepatitis Treatment Industry Restraints
3 Global Growth Perspective
  1. 3.1 Global Nonalcoholic Steatohepatitis Treatment Market Perspective (2021-2032)
  2. 3.2 Global Nonalcoholic Steatohepatitis Treatment Growth Trends by Region
  3. 3.2.1 Global Nonalcoholic Steatohepatitis Treatment Market Size by Region: 2021 VS 2025 VS 2032
  4. 3.2.2 Global Nonalcoholic Steatohepatitis Treatment Market Size by Region (2021-2026)
  5. 3.2.3 Global Nonalcoholic Steatohepatitis Treatment Market Size by Region (2027-2032)
4 Competitive Landscape by Players
  1. 4.1 Global Nonalcoholic Steatohepatitis Treatment Revenue by Players
  2. 4.1.1 Global Nonalcoholic Steatohepatitis Treatment Revenue by Players (2021-2026)
  3. 4.1.2 Global Nonalcoholic Steatohepatitis Treatment Revenue Market Share by Players (2021-2026)
  4. 4.1.3 Global Nonalcoholic Steatohepatitis Treatment Players Revenue Share Top 10 and Top 5 in 2025
  5. 4.2 Global Nonalcoholic Steatohepatitis Treatment Key Players Ranking, 2024 VS 2025 VS 2026
  6. 4.3 Global Nonalcoholic Steatohepatitis Treatment Key Players Headquarters & Area Served
  7. 4.4 Global Nonalcoholic Steatohepatitis Treatment Players, Product Type & Application
  8. 4.5 Global Nonalcoholic Steatohepatitis Treatment Players Establishment Date
  9. 4.6 Market Competitive Analysis
  10. 4.6.1 Global Nonalcoholic Steatohepatitis Treatment Market CR5 and HHI
  11. 4.6.3 2025 Nonalcoholic Steatohepatitis Treatment Tier 1, Tier 2, and Tier 3
5 Nonalcoholic Steatohepatitis Treatment Market Size by Type
  1. 5.1 Global Nonalcoholic Steatohepatitis Treatment Revenue by Type (2021 VS 2025 VS 2032)
  2. 5.2 Global Nonalcoholic Steatohepatitis Treatment Revenue by Type (2021-2032)
  3. 5.3 Global Nonalcoholic Steatohepatitis Treatment Revenue Market Share by Type (2021-2032)
6 Nonalcoholic Steatohepatitis Treatment Market Size by Application
  1. 6.1 Global Nonalcoholic Steatohepatitis Treatment Revenue by Application (2021 VS 2025 VS 2032)
  2. 6.2 Global Nonalcoholic Steatohepatitis Treatment Revenue by Application (2021-2032)
  3. 6.3 Global Nonalcoholic Steatohepatitis Treatment Revenue Market Share by Application (2021-2032)
7 Company Profiles
  1. 7.1 Arena Pharmaceuticals
  2. 7.1.1 Arena Pharmaceuticals Company Information
  3. 7.1.2 Arena Pharmaceuticals Business Overview
  4. 7.1.3 Arena Pharmaceuticals Nonalcoholic Steatohepatitis Treatment Revenue and Gross Margin (2021-2026)
  5. 7.1.4 Arena Pharmaceuticals Nonalcoholic Steatohepatitis Treatment Product Portfolio
  6. 7.1.5 Arena Pharmaceuticals Recent Developments
  7. 7.2 Arisaph Pharmaceuticals
  8. 7.2.1 Arisaph Pharmaceuticals Company Information
  9. 7.2.2 Arisaph Pharmaceuticals Business Overview
  10. 7.2.3 Arisaph Pharmaceuticals Nonalcoholic Steatohepatitis Treatment Revenue and Gross Margin (2021-2026)
  11. 7.2.4 Arisaph Pharmaceuticals Nonalcoholic Steatohepatitis Treatment Product Portfolio
  12. 7.2.5 Arisaph Pharmaceuticals Recent Developments
  13. 7.3 Cempra Pharmaceuticals
  14. 7.3.1 Cempra Pharmaceuticals Company Information
  15. 7.3.2 Cempra Pharmaceuticals Business Overview
  16. 7.3.3 Cempra Pharmaceuticals Nonalcoholic Steatohepatitis Treatment Revenue and Gross Margin (2021-2026)
  17. 7.3.4 Cempra Pharmaceuticals Nonalcoholic Steatohepatitis Treatment Product Portfolio
  18. 7.3.5 Cempra Pharmaceuticals Recent Developments
  19. 7.4 Galectin Therapeutics
  20. 7.4.1 Galectin Therapeutics Company Information
  21. 7.4.2 Galectin Therapeutics Business Overview
  22. 7.4.3 Galectin Therapeutics Nonalcoholic Steatohepatitis Treatment Revenue and Gross Margin (2021-2026)
  23. 7.4.4 Galectin Therapeutics Nonalcoholic Steatohepatitis Treatment Product Portfolio
  24. 7.4.5 Galectin Therapeutics Recent Developments
  25. 7.5 Galmed Pharmaceuticals
  26. 7.5.1 Galmed Pharmaceuticals Company Information
  27. 7.5.2 Galmed Pharmaceuticals Business Overview
  28. 7.5.3 Galmed Pharmaceuticals Nonalcoholic Steatohepatitis Treatment Revenue and Gross Margin (2021-2026)
  29. 7.5.4 Galmed Pharmaceuticals Nonalcoholic Steatohepatitis Treatment Product Portfolio
  30. 7.5.5 Galmed Pharmaceuticals Recent Developments
  31. 7.6 Genfit
  32. 7.6.1 Genfit Company Information
  33. 7.6.2 Genfit Business Overview
  34. 7.6.3 Genfit Nonalcoholic Steatohepatitis Treatment Revenue and Gross Margin (2021-2026)
  35. 7.6.4 Genfit Nonalcoholic Steatohepatitis Treatment Product Portfolio
  36. 7.6.5 Genfit Recent Developments
  37. 7.7 Gilead
  38. 7.7.1 Gilead Company Information
  39. 7.7.2 Gilead Business Overview
  40. 7.7.3 Gilead Nonalcoholic Steatohepatitis Treatment Revenue and Gross Margin (2021-2026)
  41. 7.7.4 Gilead Nonalcoholic Steatohepatitis Treatment Product Portfolio
  42. 7.7.5 Gilead Recent Developments
  43. 7.8 Novo Nordisk
  44. 7.8.1 Novo Nordisk Company Information
  45. 7.8.2 Novo Nordisk Business Overview
  46. 7.8.3 Novo Nordisk Nonalcoholic Steatohepatitis Treatment Revenue and Gross Margin (2021-2026)
  47. 7.8.4 Novo Nordisk Nonalcoholic Steatohepatitis Treatment Product Portfolio
  48. 7.8.5 Novo Nordisk Recent Developments
  49. 7.9 Vivus
  50. 7.9.1 Vivus Company Information
  51. 7.9.2 Vivus Business Overview
  52. 7.9.3 Vivus Nonalcoholic Steatohepatitis Treatment Revenue and Gross Margin (2021-2026)
  53. 7.9.4 Vivus Nonalcoholic Steatohepatitis Treatment Product Portfolio
  54. 7.9.5 Vivus Recent Developments
  55. 7.10 AstraZeneca
  56. 7.10.1 AstraZeneca Company Information
  57. 7.10.2 AstraZeneca Business Overview
  58. 7.10.3 AstraZeneca Nonalcoholic Steatohepatitis Treatment Revenue and Gross Margin (2021-2026)
  59. 7.10.4 AstraZeneca Nonalcoholic Steatohepatitis Treatment Product Portfolio
  60. 7.10.5 AstraZeneca Recent Developments
  61. 7.11 GSK
  62. 7.11.1 GSK Company Information
  63. 7.11.2 GSK Business Overview
  64. 7.11.3 GSK Nonalcoholic Steatohepatitis Treatment Revenue and Gross Margin (2021-2026)
  65. 7.11.4 GSK Nonalcoholic Steatohepatitis Treatment Product Portfolio
  66. 7.11.5 GSK Recent Developments
  67. 7.12 Roche
  68. 7.12.1 Roche Company Information
  69. 7.12.2 Roche Business Overview
  70. 7.12.3 Roche Nonalcoholic Steatohepatitis Treatment Revenue and Gross Margin (2021-2026)
  71. 7.12.4 Roche Nonalcoholic Steatohepatitis Treatment Product Portfolio
  72. 7.12.5 Roche Recent Developments
8 North America
  1. 8.1 North America Nonalcoholic Steatohepatitis Treatment Revenue (2021-2032)
  2. 8.2 North America Nonalcoholic Steatohepatitis Treatment Revenue by Type (2021-2032)
  3. 8.2.1 North America Nonalcoholic Steatohepatitis Treatment Revenue by Type (2021-2026)
  4. 8.2.2 North America Nonalcoholic Steatohepatitis Treatment Revenue by Type (2027-2032)
  5. 8.3 North America Nonalcoholic Steatohepatitis Treatment Revenue Share by Type (2021-2032)
  6. 8.4 North America Nonalcoholic Steatohepatitis Treatment Revenue by Application (2021-2032)
  7. 8.4.1 North America Nonalcoholic Steatohepatitis Treatment Revenue by Application (2021-2026)
  8. 8.4.2 North America Nonalcoholic Steatohepatitis Treatment Revenue by Application (2027-2032)
  9. 8.5 North America Nonalcoholic Steatohepatitis Treatment Revenue Share by Application (2021-2032)
  10. 8.6 North America Nonalcoholic Steatohepatitis Treatment Revenue by Country
  11. 8.6.1 North America Nonalcoholic Steatohepatitis Treatment Revenue by Country (2021 VS 2025 VS 2032)
  12. 8.6.2 North America Nonalcoholic Steatohepatitis Treatment Revenue by Country (2021-2026)
  13. 8.6.3 North America Nonalcoholic Steatohepatitis Treatment Revenue by Country (2027-2032)
  14. 8.6.4 United States
  15. 8.6.5 Canada
9 Europe
  1. 9.1 Europe Nonalcoholic Steatohepatitis Treatment Revenue (2021-2032)
  2. 9.2 Europe Nonalcoholic Steatohepatitis Treatment Revenue by Type (2021-2032)
  3. 9.2.1 Europe Nonalcoholic Steatohepatitis Treatment Revenue by Type (2021-2026)
  4. 9.2.2 Europe Nonalcoholic Steatohepatitis Treatment Revenue by Type (2027-2032)
  5. 9.3 Europe Nonalcoholic Steatohepatitis Treatment Revenue Share by Type (2021-2032)
  6. 9.4 Europe Nonalcoholic Steatohepatitis Treatment Revenue by Application (2021-2032)
  7. 9.4.1 Europe Nonalcoholic Steatohepatitis Treatment Revenue by Application (2021-2026)
  8. 9.4.2 Europe Nonalcoholic Steatohepatitis Treatment Revenue by Application (2027-2032)
  9. 9.5 Europe Nonalcoholic Steatohepatitis Treatment Revenue Share by Application (2021-2032)
  10. 9.6 Europe Nonalcoholic Steatohepatitis Treatment Revenue by Country
  11. 9.6.1 Europe Nonalcoholic Steatohepatitis Treatment Revenue by Country (2021 VS 2025 VS 2032)
  12. 9.6.2 Europe Nonalcoholic Steatohepatitis Treatment Revenue by Country (2021-2026)
  13. 9.6.3 Europe Nonalcoholic Steatohepatitis Treatment Revenue by Country (2027-2032)
  14. 9.6.4 Germany
  15. 9.6.5 France
  16. 9.6.6 U.K.
  17. 9.6.7 Italy
  18. 9.6.8 Netherlands
10 China
  1. 10.1 China Nonalcoholic Steatohepatitis Treatment Revenue (2021-2032)
  2. 10.2 China Nonalcoholic Steatohepatitis Treatment Revenue by Type (2021-2032)
  3. 10.2.1 China Nonalcoholic Steatohepatitis Treatment Revenue by Type (2021-2026)
  4. 10.2.2 China Nonalcoholic Steatohepatitis Treatment Revenue by Type (2027-2032)
  5. 10.3 China Nonalcoholic Steatohepatitis Treatment Revenue Share by Type (2021-2032)
  6. 10.4 China Nonalcoholic Steatohepatitis Treatment Revenue by Application (2021-2032)
  7. 10.4.1 China Nonalcoholic Steatohepatitis Treatment Revenue by Application (2021-2026)
  8. 10.4.2 China Nonalcoholic Steatohepatitis Treatment Revenue by Application (2027-2032)
  9. 10.5 China Nonalcoholic Steatohepatitis Treatment Revenue Share by Application (2021-2032)
11 Asia (Excluding China)
  1. 11.1 Asia Nonalcoholic Steatohepatitis Treatment Revenue (2021-2032)
  2. 11.2 Asia Nonalcoholic Steatohepatitis Treatment Revenue by Type (2021-2032)
  3. 11.2.1 Asia Nonalcoholic Steatohepatitis Treatment Revenue by Type (2021-2026)
  4. 11.2.2 Asia Nonalcoholic Steatohepatitis Treatment Revenue by Type (2027-2032)
  5. 11.3 Asia Nonalcoholic Steatohepatitis Treatment Revenue Share by Type (2021-2032)
  6. 11.4 Asia Nonalcoholic Steatohepatitis Treatment Revenue by Application (2021-2032)
  7. 11.4.1 Asia Nonalcoholic Steatohepatitis Treatment Revenue by Application (2021-2026)
  8. 11.4.2 Asia Nonalcoholic Steatohepatitis Treatment Revenue by Application (2027-2032)
  9. 11.5 Asia Nonalcoholic Steatohepatitis Treatment Revenue Share by Application (2021-2032)
  10. 11.6 Asia Nonalcoholic Steatohepatitis Treatment Revenue by Country
  11. 11.6.1 Asia Nonalcoholic Steatohepatitis Treatment Revenue by Country (2021 VS 2025 VS 2032)
  12. 11.6.2 Asia Nonalcoholic Steatohepatitis Treatment Revenue by Country (2021-2026)
  13. 11.6.3 Asia Nonalcoholic Steatohepatitis Treatment Revenue by Country (2027-2032)
  14. 11.6.4 Japan
  15. 11.6.5 South Korea
  16. 11.6.6 India
  17. 11.6.7 Australia
  18. 11.6.8 Taiwan
  19. 11.6.9 Southeast Asia
12 South America, Middle East and Africa
  1. 12.1 SAMEA Nonalcoholic Steatohepatitis Treatment Revenue (2021-2032)
  2. 12.2 SAMEA Nonalcoholic Steatohepatitis Treatment Revenue by Type (2021-2032)
  3. 12.2.1 SAMEA Nonalcoholic Steatohepatitis Treatment Revenue by Type (2021-2026)
  4. 12.2.2 SAMEA Nonalcoholic Steatohepatitis Treatment Revenue by Type (2027-2032)
  5. 12.3 SAMEA Nonalcoholic Steatohepatitis Treatment Revenue Share by Type (2021-2032)
  6. 12.4 SAMEA Nonalcoholic Steatohepatitis Treatment Revenue by Application (2021-2032)
  7. 12.4.1 SAMEA Nonalcoholic Steatohepatitis Treatment Revenue by Application (2021-2026)
  8. 12.4.2 SAMEA Nonalcoholic Steatohepatitis Treatment Revenue by Application (2027-2032)
  9. 12.5 SAMEA Nonalcoholic Steatohepatitis Treatment Revenue Share by Application (2021-2032)
  10. 12.6 SAMEA Nonalcoholic Steatohepatitis Treatment Revenue by Country
  11. 12.6.1 SAMEA Nonalcoholic Steatohepatitis Treatment Revenue by Country (2021 VS 2025 VS 2032)
  12. 12.6.2 SAMEA Nonalcoholic Steatohepatitis Treatment Revenue by Country (2021-2026)
  13. 12.6.3 SAMEA Nonalcoholic Steatohepatitis Treatment Revenue by Country (2027-2032)
  14. 12.6.4 Brazil
  15. 12.6.5 Argentina
  16. 12.6.6 Chile
  17. 12.6.7 Colombia
  18. 12.6.8 Peru
  19. 12.6.9 Saudi Arabia
  20. 12.6.10 Israel
  21. 12.6.11 UAE
  22. 12.6.12 Turkey
  23. 12.6.13 Iran
  24. 12.6.14 Egypt
13 Concluding Insights
    14 Appendix
    1. 14.1 Reasons for Doing This Study
    2. 14.2 Research Methodology
    3. 14.3 Research Process
    4. 14.4 Authors List of This Report
    5. 14.5 Data Source
    6. 14.5.1 Secondary Sources
    7. 14.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst